Stereotactic radiosurgery for lung cancer that has spread to the brain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of stereotactic radiosurgery (SRS) as a treatment for patients newly diagnosed with brain metastases from small cell lung cancer (SCLC). Participants will undergo SRS to target up to 10 brain metastases, with the aim of improving treatment outcomes. The study will include patients aged 18 and older who meet specific performance status criteria and have a confirmed diagnosis of SCLC. The research will assess the safety and efficacy of this intervention in managing brain metastases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologic diagnosis of small cell lung cancer
* Radiographic diagnosis of up to 20 brain metastases on contrast-enhanced MRI
* Age 18 and above
* Performance status KPS 60-100/ECOG 0-2
* Female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment
* The patient or legally authorized representative is able to provide informed consent

Exclusion Criteria:

* Unable to undergo contrast-enhanced MRI brain
* Leptomeningeal disease confirmed on lumbar puncture, MRI brain, or MRI spine
* Pregnant or lactating women
* Prior brain-directed radiotherapy
* Uncontrolled systemic disease without reasonable systemic therapy options felt likely to result in death as observed on CT or PET/CT imaging, no more than 3 months before study enrollment

Where it's running

• Memorial Sloan Kettering at Basking Ridge
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Suffolk - Commack
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Luke Pike, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Luke Pike, MD
• Email: PikeL@mskcc.org
• Phone: 201-775-7604

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• Using a new imaging agent to detect lung cancer spread

  This study is testing a new imaging method to see if it can better detect the spread of lung cancer, especially to the brain, in patients with Non-Small Cell Lung Cancer.

  Recruiting Phase 1 University of California, Davis · Sacramento, California · NCT05452005

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Autologous B7-H3 CAR T Cells in Advanced Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

  This study tests a patient’s own B7-H3 CAR T cells to see if they can help people 18 and older whose small cell lung cancer or EPNEC has come back or hasn’t responded to prior treatment.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07509034

• Tarlatamab for Small Cell Lung Cancer with Brain Metastases

  This phase II study tests whether tarlatamab can help adults with small cell lung cancer that has spread to the brain, by treating both systemic disease and brain tumors.

  Recruiting at 3 sites Phase 2 Maastricht University Medical Center · Amsterdam and 3 other locations · NCT07402343

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.